Statement on COVID-19 from Hepatitis B Foundation Scientific and Medical Advisory Board to the hepatitis B community <<click here>>

Welcome to our Liver Cancer Connect Program

grandpa

 

Find Clinical Trials Near Me!

hepbfoundation livercancer banner 1

webinar series


newly diagnosed

Liver Cancer Connect is a dedicated program of the Hepatitis B Foundation that was created to provide individuals and families with the information and support they need when facing the challenge of primary liver cancer. Although this is a serious diagnosis, there is good reason to have hope because of the many advances made in the early detection, management and treatment of liver cancer.

In the News

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (ASCOPost, May 2020)

Atezolizumab combination improves survival in HCC (Cancer Letter, May 2020)

COVID 2019: What People With Cancer Need to Know (Cancer.net, June 2020)

U.S. FDA approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® GALAD score to Help Diagnose HCC

Pan tumor clinical trial is actively recruiting to investigate the effects of nivolumab when given under the skin with or without rHuPH20. Learn more! 

FDA has approved cabozantinib (CABOMETYX, Exelixis, Inc.) for patients with hepatocellular carcinoma who have been previously treated with sorafenib

DNA search finds people resistant to liver disease. Can we mimic this effect with a drug? Regeneron and Alnylam Pharmaceutical to partner  

Newly discovered anti-cancer protein LHPP prevents uncontrolled proliferation of cancer cells in the liver and may serve as a biomarker for the diagnosis & prognosis of liver cancer 

Get Connected

square facebook 512Twitter icon horizontal2